A survey of Illinois physicians participating in the state’s Opioid Alternative Patient Program revealed that cannabis as opioid alternative physician education remains a critical need. Even early adopter clinicians emphasized educational gaps as a primary implementation barrier, highlighting broader challenges in integrating cannabis medicine into clinical practice.
Drug policy and culture: A cross-national comparative study using Hofstede’s index.
Cross-national analysis of 25 countries reveals that cultural factors in cannabis policy significantly influence national drug policy frameworks. Countries with lower power distance and uncertainty avoidance demonstrate more progressive approaches to controlled substances, suggesting cultural barriers may impact medical cannabis access beyond economic and institutional factors.
What Federal Cannabis Rescheduling Means for Care
Cannabis Schedule III rescheduling marks a major shift in how cannabis is classified and understood at the federal level. This change begins to align policy with clinical reality, affecting research, documentation, and patient access. Cannabis Schedule III rescheduling does not solve every clinical challenge, but it opens the door to more structured and evidence-driven care.
Contentious legality in decentralized governance: The rise and decline of cannabis social clubs in Spain.
A comprehensive policy analysis reveals how Spanish cannabis social clubs legal framework exploited legal ambiguities to create community-based alternatives to illicit markets. The study demonstrates how grassroots activism and strategic legal interpretation temporarily created contested spaces for collective cannabis activities before regulatory closure. This research offers insights into cannabis policy reform through social mobilization rather than legislative action.
What the DOJ Cannabis Order Means for Patients and Clinicians
The medical cannabis Schedule III order is a major federal policy change, but it is not the same as new clinical proof. This Evidence Watch explains what the DOJ action may mean for research access, patient care, and regulated medical cannabis programs. It also clarifies what Schedule III does not show about cannabis safety, dosing, or effectiveness for specific conditions.
Cannabis Rescheduling Is Not the Story People Think It Is
The cannabis rescheduling clinical impact is being widely misunderstood. While federal policy shifts from Schedule I to Schedule III signal progress, they do not define how cannabis should be used in medical care. This analysis clarifies what changes, what does not, and what clinicians and patients should actually take from this moment.
Sick American basketball player jailed in Indonesia over cannabis gummies pleads for early release
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Travel MedicineLegal RiskPatient SafetyInternational LawCannabis Policy Why This MattersThis case highlights the critical disconnect...
Medical Cannabis Authorization Linked to Modestly Higher Heart Failure Risk in Large Ontario Study
Patients exposed to cannabis had a higher risk for the primary outcome with a hazard ratio of 1.15 (95% CI: 1.06–1.25). The results suggest a higher risk of heart failure-related events, including emergency department visits, hospitalizations, and outpatient consultations, among patients who were authorized cannabis for medical purposes.
Falkville man arrested with 6 pounds of marijuana, over 1000 THC vapes – WAFF
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Vaping SafetyUnregulated ProductsCannabis PolicyHarm ReductionThc Concentrates Why This MattersLarge-scale arrests involving concentrated THC products...
High-Potency Cannabis: America’s New Pastime and Psychiatry’s Next Challenge
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. Mental HealthTHCSafetyPolicyResearch Why This Matters Clinicians need to understand that high-potency cannabis products are increasingly...